Q4 EPS Estimates for bluebird bio Raised by Leerink Partnrs

bluebird bio, Inc. (NASDAQ:BLUE) – Equities research analysts at Leerink Partnrs boosted their Q4 2024 earnings per share (EPS) estimates for shares of bluebird bio in a note issued to investors on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now expects that the biotechnology company will earn ($4.42) per share for the quarter, up from their previous forecast of ($4.47). The consensus estimate for bluebird bio’s current full-year earnings is ($27.17) per share. Leerink Partnrs also issued estimates for bluebird bio’s FY2025 earnings at ($6.42) EPS.

Several other equities analysts also recently issued reports on BLUE. JPMorgan Chase & Co. downgraded shares of bluebird bio from a “neutral” rating to an “underweight” rating in a report on Friday, November 15th. Barclays lifted their target price on shares of bluebird bio from $2.00 to $40.00 and gave the company an “overweight” rating in a research note on Tuesday, December 31st. Royal Bank of Canada restated a “sector perform” rating and set a $80.00 price target on shares of bluebird bio in a research report on Friday, November 15th. StockNews.com initiated coverage on bluebird bio in a research report on Friday, December 20th. They issued a “sell” rating for the company. Finally, Bank of America cut bluebird bio from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $60.00 to $10.00 in a report on Friday, November 15th. Three research analysts have rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $49.14.

bluebird bio Stock Down 0.9 %

NASDAQ BLUE opened at $7.80 on Friday. bluebird bio has a 1-year low of $5.80 and a 1-year high of $38.40. The company has a market capitalization of $75.82 million, a price-to-earnings ratio of -0.21 and a beta of 0.68. The stock’s 50 day moving average is $8.17 and its two-hundred day moving average is $11.86. The company has a current ratio of 0.51, a quick ratio of 0.33 and a debt-to-equity ratio of 0.37.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Verition Fund Management LLC acquired a new position in shares of bluebird bio during the 3rd quarter worth about $42,000. SG Americas Securities LLC boosted its position in bluebird bio by 152.4% during the third quarter. SG Americas Securities LLC now owns 122,855 shares of the biotechnology company’s stock valued at $64,000 after purchasing an additional 74,185 shares during the last quarter. Captrust Financial Advisors grew its stake in bluebird bio by 48.2% in the third quarter. Captrust Financial Advisors now owns 237,648 shares of the biotechnology company’s stock valued at $123,000 after purchasing an additional 77,293 shares in the last quarter. Barclays PLC increased its position in shares of bluebird bio by 273.7% during the 3rd quarter. Barclays PLC now owns 252,062 shares of the biotechnology company’s stock worth $130,000 after purchasing an additional 184,605 shares during the last quarter. Finally, Rhumbline Advisers raised its stake in shares of bluebird bio by 25.4% during the 2nd quarter. Rhumbline Advisers now owns 292,436 shares of the biotechnology company’s stock worth $288,000 after purchasing an additional 59,219 shares in the last quarter. 87.43% of the stock is currently owned by institutional investors.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.